Sindrome da anticorpi antifosfolipidi in corso di leucemia linfatica cronica. Associazione con autoanticorpi anti-fattore VIII

Translated title of the contribution: Antiphospholipid syndrome in a chronic lymphocytic leukemia patient. Association with anti-factor VII inhibitors

A. Ghirarduzzi, M. Silingardi, M. D'Inca, E. Tincani

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Activated partial thromboplastin time may be prolonged as the result of either of two different autoimmune complications of chronic lymphocytic leukemia: the development of antiphospholipid antibodies, such as lupus anticoagulant or anticardiolipin antibodies, or anti-factor VIII inhibitors, such as acquired hemophilia A. In the rare simultaneous occurrence of both inhibitors, differential diagnosis of a prolonged activated partial thromboplastin time poses a number of problems during laboratory work-up, due to mutual interference of the commonly performed tests. Only careful clinical follow-up can disclose the significance of the laboratory findings. We report the case of concurrent antiphospholipid antibodies (lupus anticoagulant positivity, anticardiolipin antibodies; IgM 3880 MPL/mL and IgG 265 GPL/mL) and anti-factor VIII antibodies (46.8 Bethesda Units) in a patient with chronic B-cell lymphocytic leukemia who had prolonged activated partial thromboplastin time (78.8 s). The relationship between lymphoproliferative and antiphospholipid syndrome, laboratory workup in the case of the association of antiphospholipid and anti-factor VIII antibodies, and related problems that occur during clinical management of the patient are also discussed.

Original languageItalian
Pages (from-to)46-50
Number of pages5
JournalAnnali Italiani di Medicina Interna
Volume14
Issue number1
Publication statusPublished - 1999

Fingerprint

Factor VII
Antiphospholipid Syndrome
Partial Thromboplastin Time
Factor VIII
B-Cell Chronic Lymphocytic Leukemia
Lupus Coagulation Inhibitor
Anticardiolipin Antibodies
Antiphospholipid Antibodies
Antibodies
Immunoglobulin M
Differential Diagnosis
Immunoglobulin G

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Sindrome da anticorpi antifosfolipidi in corso di leucemia linfatica cronica. Associazione con autoanticorpi anti-fattore VIII. / Ghirarduzzi, A.; Silingardi, M.; D'Inca, M.; Tincani, E.

In: Annali Italiani di Medicina Interna, Vol. 14, No. 1, 1999, p. 46-50.

Research output: Contribution to journalArticle

@article{a756c1b1d53742709f0aafc0735cf654,
title = "Sindrome da anticorpi antifosfolipidi in corso di leucemia linfatica cronica. Associazione con autoanticorpi anti-fattore VIII",
abstract = "Activated partial thromboplastin time may be prolonged as the result of either of two different autoimmune complications of chronic lymphocytic leukemia: the development of antiphospholipid antibodies, such as lupus anticoagulant or anticardiolipin antibodies, or anti-factor VIII inhibitors, such as acquired hemophilia A. In the rare simultaneous occurrence of both inhibitors, differential diagnosis of a prolonged activated partial thromboplastin time poses a number of problems during laboratory work-up, due to mutual interference of the commonly performed tests. Only careful clinical follow-up can disclose the significance of the laboratory findings. We report the case of concurrent antiphospholipid antibodies (lupus anticoagulant positivity, anticardiolipin antibodies; IgM 3880 MPL/mL and IgG 265 GPL/mL) and anti-factor VIII antibodies (46.8 Bethesda Units) in a patient with chronic B-cell lymphocytic leukemia who had prolonged activated partial thromboplastin time (78.8 s). The relationship between lymphoproliferative and antiphospholipid syndrome, laboratory workup in the case of the association of antiphospholipid and anti-factor VIII antibodies, and related problems that occur during clinical management of the patient are also discussed.",
author = "A. Ghirarduzzi and M. Silingardi and M. D'Inca and E. Tincani",
year = "1999",
language = "Italian",
volume = "14",
pages = "46--50",
journal = "Annali Italiani di Medicina Interna",
issn = "0393-9340",
publisher = "CEPI s.r.l.",
number = "1",

}

TY - JOUR

T1 - Sindrome da anticorpi antifosfolipidi in corso di leucemia linfatica cronica. Associazione con autoanticorpi anti-fattore VIII

AU - Ghirarduzzi, A.

AU - Silingardi, M.

AU - D'Inca, M.

AU - Tincani, E.

PY - 1999

Y1 - 1999

N2 - Activated partial thromboplastin time may be prolonged as the result of either of two different autoimmune complications of chronic lymphocytic leukemia: the development of antiphospholipid antibodies, such as lupus anticoagulant or anticardiolipin antibodies, or anti-factor VIII inhibitors, such as acquired hemophilia A. In the rare simultaneous occurrence of both inhibitors, differential diagnosis of a prolonged activated partial thromboplastin time poses a number of problems during laboratory work-up, due to mutual interference of the commonly performed tests. Only careful clinical follow-up can disclose the significance of the laboratory findings. We report the case of concurrent antiphospholipid antibodies (lupus anticoagulant positivity, anticardiolipin antibodies; IgM 3880 MPL/mL and IgG 265 GPL/mL) and anti-factor VIII antibodies (46.8 Bethesda Units) in a patient with chronic B-cell lymphocytic leukemia who had prolonged activated partial thromboplastin time (78.8 s). The relationship between lymphoproliferative and antiphospholipid syndrome, laboratory workup in the case of the association of antiphospholipid and anti-factor VIII antibodies, and related problems that occur during clinical management of the patient are also discussed.

AB - Activated partial thromboplastin time may be prolonged as the result of either of two different autoimmune complications of chronic lymphocytic leukemia: the development of antiphospholipid antibodies, such as lupus anticoagulant or anticardiolipin antibodies, or anti-factor VIII inhibitors, such as acquired hemophilia A. In the rare simultaneous occurrence of both inhibitors, differential diagnosis of a prolonged activated partial thromboplastin time poses a number of problems during laboratory work-up, due to mutual interference of the commonly performed tests. Only careful clinical follow-up can disclose the significance of the laboratory findings. We report the case of concurrent antiphospholipid antibodies (lupus anticoagulant positivity, anticardiolipin antibodies; IgM 3880 MPL/mL and IgG 265 GPL/mL) and anti-factor VIII antibodies (46.8 Bethesda Units) in a patient with chronic B-cell lymphocytic leukemia who had prolonged activated partial thromboplastin time (78.8 s). The relationship between lymphoproliferative and antiphospholipid syndrome, laboratory workup in the case of the association of antiphospholipid and anti-factor VIII antibodies, and related problems that occur during clinical management of the patient are also discussed.

UR - http://www.scopus.com/inward/record.url?scp=0032980779&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032980779&partnerID=8YFLogxK

M3 - Articolo

C2 - 10528424

AN - SCOPUS:0032980779

VL - 14

SP - 46

EP - 50

JO - Annali Italiani di Medicina Interna

JF - Annali Italiani di Medicina Interna

SN - 0393-9340

IS - 1

ER -